688428 诺诚健华
已收盘 05-29 15:00:01
资讯
新帖
简况
诺诚健华(688428.SH):国家药监局受理奥布替尼治疗原发免疫性血小板减少症的新药上市申请
智通财经 · 05-28 16:23
诺诚健华(688428.SH):国家药监局受理奥布替尼治疗原发免疫性血小板减少症的新药上市申请
诺诚健华奥布替尼获澳大利亚TGA批准用于治疗复发或难治性套细胞淋巴瘤
美股速递 · 05-27
诺诚健华奥布替尼获澳大利亚TGA批准用于治疗复发或难治性套细胞淋巴瘤
诺诚健华(688428.SH):奥布替尼获得澳大利亚药品管理局批准上市
智通财经 · 05-27
诺诚健华(688428.SH):奥布替尼获得澳大利亚药品管理局批准上市
诺诚健华(688428)披露2024年科创板限制性股票激励计划首次授予部分第一个归属期符合归属条件的公告,5月25日股价上涨0.28%
证券之星 · 05-25
诺诚健华(688428)披露2024年科创板限制性股票激励计划首次授予部分第一个归属期符合归属条件的公告,5月25日股价上涨0.28%
5月21日诺诚健华涨5.55%,富国精准医疗混合A基金重仓该股
证券之星 · 05-21
5月21日诺诚健华涨5.55%,富国精准医疗混合A基金重仓该股
诺诚健华涨5.55%,长城国瑞证券一个月前给出“买入”评级
证券之星 · 05-21
诺诚健华涨5.55%,长城国瑞证券一个月前给出“买入”评级
港股异动 | 诺诚健华(09969)午后涨超4% 抗炎症创新药ICP054完成首例受试者入组
智通财经 · 05-21
港股异动 | 诺诚健华(09969)午后涨超4% 抗炎症创新药ICP054完成首例受试者入组
诺诚健华CEO崔霁松:研发、商业化、全球化并行丨21健谈
21世纪经济报道 · 05-20
诺诚健华CEO崔霁松:研发、商业化、全球化并行丨21健谈
股市必读:诺诚健华(688428)5月15日披露最新机构调研信息
证券之星 · 05-18
股市必读:诺诚健华(688428)5月15日披露最新机构调研信息
每周股票复盘:诺诚健华(688428)Q1净利增607.72%
证券之星 · 05-17
每周股票复盘:诺诚健华(688428)Q1净利增607.72%
诺诚健华(688428)披露ICP-054(ZB021)完成首例受试者入组公告,5月14日股价下跌3.46%
证券之星 · 05-14
诺诚健华(688428)披露ICP-054(ZB021)完成首例受试者入组公告,5月14日股价下跌3.46%
诺诚健华宣布首例受试者接受潜在同类最佳口服IL-17Aa/Af抑制剂ICP-054一期临床试验给药
美股速递 · 05-13
诺诚健华宣布首例受试者接受潜在同类最佳口服IL-17Aa/Af抑制剂ICP-054一期临床试验给药
诺诚健华(09969):ICP-054 (ZB021)的1期临床试验完成首例受试者入组
智通财经 · 05-13
诺诚健华(09969):ICP-054 (ZB021)的1期临床试验完成首例受试者入组
每周股票复盘:诺诚健华(688428)将召开2025年度业绩说明会
证券之星 · 05-10
每周股票复盘:诺诚健华(688428)将召开2025年度业绩说明会
诺诚健华(688428)披露证券变动月报表,5月8日股价下跌2.48%
证券之星 · 05-08
诺诚健华(688428)披露证券变动月报表,5月8日股价下跌2.48%
诺诚健华TYK2抑制剂ICP-488在华获批开展干燥综合征II期临床试验
美股速递 · 05-08
诺诚健华TYK2抑制剂ICP-488在华获批开展干燥综合征II期临床试验
诺诚健华(688428)披露持股5%以上股东权益变动触及1%刻度公告,5月6日股价下跌1.28%
证券之星 · 05-06
诺诚健华(688428)披露持股5%以上股东权益变动触及1%刻度公告,5月6日股价下跌1.28%
每周股票复盘:诺诚健华(688428)股东权益变动触及1%刻度
证券之星 · 05-02
每周股票复盘:诺诚健华(688428)股东权益变动触及1%刻度
港股异动 | 诺诚健华(09969)涨近3% Mesutoclax治疗髓系恶性肿瘤研究入选ASCO 2026年会口头报告
智通财经 · 04-28
港股异动 | 诺诚健华(09969)涨近3% Mesutoclax治疗髓系恶性肿瘤研究入选ASCO 2026年会口头报告
诺诚健华(688428)披露2026年股东周年大会通知,4月27日股价下跌1.97%
证券之星 · 04-27
诺诚健华(688428)披露2026年股东周年大会通知,4月27日股价下跌1.97%
加载更多
公司概况
公司名称:
诺诚健华医药有限公司
所属行业:
医药制造业
上市日期:
2022-09-21
主营业务:
诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼。
发行价格:
11.03
{"stockData":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":24.45,"timestamp":1780038001000,"preClose":24.45,"halted":0,"volume":12876093,"delay":0,"changeRate":0,"floatShares":268000000,"shares":1764999999,"eps":0.4139,"marketStatus":"已收盘","change":0,"latestTime":"05-29 15:00:01","open":24.86,"high":25.26,"low":23.7,"amount":315000000,"amplitude":0.0638,"askPrice":24.46,"askSize":29,"bidPrice":24.45,"bidSize":26,"shortable":0,"etf":0,"ttmEps":0.4139,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780277400000},"marketStatusCode":5,"adr":0,"adjPreClose":24.45,"symbolType":"stock_kcb","openAndCloseTimeList":[[1780018200000,1780025400000],[1780030800000,1780038000000]],"highLimit":26.9,"lowLimit":22.01,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1764643952,"isCdr":false,"pbRate":5.87,"roa":"--","peRate":59.07224,"roe":"1.4%","epsLYR":0.38,"committee":0.901552,"marketValue":43146000000,"turnoverRate":0.048,"status":2,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-06-01。","afterMarket":{"amount":0,"volume":0,"close":24.45,"buyVolume":3490,"sellVolume":0,"time":1780040038866,"indexStatus":"已收盘 05-29 15:30:00","preClose":24.45},"hkstockBrief":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":11.63,"timestamp":1780042106010,"preClose":11.22,"halted":0,"volume":14983000,"delay":0,"premium":"-58.95"},"floatMarketCap":6561000000},"requestUrl":"/m/hq/s/688428","defaultTab":"news","newsList":[{"id":"2638665588","title":"诺诚健华(688428.SH):国家药监局受理奥布替尼治疗原发免疫性血小板减少症的新药上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2638665588","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638665588?lang=zh_cn&edition=full","pubTime":"2026-05-28 16:23","pubTimestamp":1779956622,"startTime":"0","endTime":"0","summary":"智通财经APP讯,诺诚健华(688428.SH)发布公告,公司自主研发的布鲁顿酪氨酸激酶(BTK)抑制剂奥布替尼用于治疗原发免疫性血小板减少症(ITP)患者的新药上市申请(NDA),近日已获国家药品监督管理局(NMPA)药品审评中心(CDE)受理。奥布替尼是公司自主研发的具有高度靶点选择性的新型BTK抑制剂。BTK是B细胞受体信号通路中的关键激酶,对活化B淋巴细胞、巨噬细胞和其他免疫细胞以及在ITP病理过程中产生致病性抗体至关重要。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447105.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","BK1161","BK0239","IPOS","BK1574","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140403571","title":"诺诚健华奥布替尼获澳大利亚TGA批准用于治疗复发或难治性套细胞淋巴瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1140403571","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140403571?lang=zh_cn&edition=full","pubTime":"2026-05-27 16:55","pubTimestamp":1779872116,"startTime":"0","endTime":"0","summary":"诺诚健华旗下药物奥布替尼(Orelabrutinib)已获得澳大利亚药品管理局(TGA)的批准,用于治疗复发或难治性套细胞淋巴瘤(MCL)。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638570074","title":"诺诚健华(688428.SH):奥布替尼获得澳大利亚药品管理局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2638570074","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638570074?lang=zh_cn&edition=full","pubTime":"2026-05-27 16:27","pubTimestamp":1779870478,"startTime":"0","endTime":"0","summary":"智通财经APP讯,诺诚健华 发布公告,近日,公司收到通知,奥布替尼已获澳大利亚药品管理局核准签发的上市许可。奥布替尼是公司自主研发的具有高度靶点选择性的新型BTK抑制剂,可有效规避脱靶效应引发的不良反应,显著提升治疗的安全性与有效性。在国际市场上,奥布替尼已在新加坡获批治疗r/rMCL和r/rMZL成年患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446563.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BK1574","09969","BK1161","BK0239","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638255631","title":"诺诚健华(688428)披露2024年科创板限制性股票激励计划首次授予部分第一个归属期符合归属条件的公告,5月25日股价上涨0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638255631","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638255631?lang=zh_cn&edition=full","pubTime":"2026-05-25 22:51","pubTimestamp":1779720677,"startTime":"0","endTime":"0","summary":"截至2026年5月25日收盘,诺诚健华报收于25.27元,较前一交易日上涨0.28%,最新总市值为445.93亿元。该股当日开盘25.13元,最高25.8元,最低24.89元,成交额达2.19亿元,换手率为3.22%。近日,诺诚健华医药有限公司披露《关于2024年科创板限制性股票激励计划首次授予部分第一个归属期符合归属条件的公告》。公告显示,公司于2026年5月25日召开董事会,审议通过相关议案。公司已履行相关审批程序,上海市方达律师事务所出具法律意见书,认为本次归属条件已成就。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500034317.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688428","BK1574","159982","09969","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637838567","title":"5月21日诺诚健华涨5.55%,富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2637838567","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637838567?lang=zh_cn&edition=full","pubTime":"2026-05-21 16:36","pubTimestamp":1779352598,"startTime":"0","endTime":"0","summary":"证券之星消息,5月21日诺诚健华涨5.55%,收盘报25.85元,换手率7.97%,成交量21.38万手,成交额5.55亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共28家,其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为31.86亿元,最新净值3.0059,较上一交易日上涨0.07%,近一年上涨6.08%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100030556.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","09969","BK0239","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637385956","title":"诺诚健华涨5.55%,长城国瑞证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2637385956","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637385956?lang=zh_cn&edition=full","pubTime":"2026-05-21 16:36","pubTimestamp":1779352591,"startTime":"0","endTime":"0","summary":"今日诺诚健华涨5.55%,收盘报25.85元。2026年3月31日,长城国瑞证券研究员胡晨曦,魏钰琪发布了对诺诚健华的研报《盈利拐点初现,商业化放量与技术授权双轮驱动》,该研报对诺诚健华给出“买入”评级。因此,我们维持其“买入”评级。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为国海证券的孔维崎、周小刚。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100030551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","09969","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637041198","title":"港股异动 | 诺诚健华(09969)午后涨超4% 抗炎症创新药ICP054完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2637041198","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637041198?lang=zh_cn&edition=full","pubTime":"2026-05-21 14:03","pubTimestamp":1779343431,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,诺诚健华午后涨超4%,截至发稿,涨3.27%,报12.32港元,成交额9032.58万港元。消息面上,诺诚健华此前发布公告,新型口服、潜在同类最佳的IL-17AA/AF抑制剂 ICP-054 的1期临床试验完成首例受试者入组。目前,全球尚无口服IL-17抑制剂获批上市或处于后期开发阶段。ICP-054的口服小分子特性,在用药便利性、患者依从性以及临床可及性上,有潜力比目前已获批的生物制剂IL-17疗法更具优势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","159992","BK4585","BK1574","688428","BK4588","09969","06978","VXUS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636815772","title":"诺诚健华CEO崔霁松:研发、商业化、全球化并行丨21健谈","url":"https://stock-news.laohu8.com/highlight/detail?id=2636815772","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636815772?lang=zh_cn&edition=full","pubTime":"2026-05-20 14:28","pubTimestamp":1779258522,"startTime":"0","endTime":"0","summary":"在科创板生物医药板块2026年一季度业绩披露落下帷幕之际,一组振奋人心的财务数据随之定格。数据显示,科创板28家创新药企业2025年合计营收约740亿元,同比增长近30%;行业净利润约16亿元,首次实现整体盈利。在行业整体向好的背景下,诺诚健华(688428.SH/09969.HK)表现尤为亮眼。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605203743359612.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605203743359612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1161","09969","BK0239","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636136500","title":"股市必读:诺诚健华(688428)5月15日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2636136500","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636136500?lang=zh_cn&edition=full","pubTime":"2026-05-18 01:43","pubTimestamp":1779039791,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘,诺诚健华报收于25.18元,下跌2.02%,换手率3.35%,成交量8.99万手,成交额2.28亿元。同时去年坦昔妥单抗和佐来曲替尼相继获批,也标志着公司从单一产品正式迈入多元化产品组合时代。随着商业化能力提升及运营效率优化,公司整体经营效率进一步改善,实现了收入增长、BD合作与研发投入之间的良性平衡。2026年第一季度,公司延续了良好的增长态势。其中,药品销售收入为4.50亿元,同比增长44.54%;总营业收入为5.29亿元,同比增长38.65%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800000728.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","BK1161","BK1574","688428","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636061921","title":"每周股票复盘:诺诚健华(688428)Q1净利增607.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636061921","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636061921?lang=zh_cn&edition=full","pubTime":"2026-05-17 02:07","pubTimestamp":1778954831,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘,诺诚健华报收于25.18元,较上周的26.35元下跌4.44%。本周,诺诚健华5月12日盘中最高价报27.52元。诺诚健华当前最新总市值444.34亿元,在化学制药板块市值排名8/150,在两市A股市值排名479/5203。本周关注点来自机构调研要点:2026年一季度净利润同比增长607.72%,延续高增长态势。公司 2026 年 1-3 月的净利润为 1.02 亿元,比上年同期净利润增长 607.72%。公司公告汇总诺诚健华医药有限公司公告,其创新药ICP-054已完成首例受试者入组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700000487.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","BK1161","688428","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635718977","title":"诺诚健华(688428)披露ICP-054(ZB021)完成首例受试者入组公告,5月14日股价下跌3.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635718977","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635718977?lang=zh_cn&edition=full","pubTime":"2026-05-14 17:43","pubTimestamp":1778751808,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘,诺诚健华报收于25.7元,较前一交易日下跌3.46%,最新总市值为453.51亿元。该股当日开盘26.6元,最高26.85元,最低25.6元,成交额达2.43亿元,换手率为3.48%。公告显示,公司创新药ICP-054已完成首例受试者入组。该药物为新型口服高效、高选择性IL-17AA/AF抑制剂,具有治疗自身免疫和炎症性疾病的潜力。公司与Zenas BioPharma合作开展I期临床试验,评估药物在健康受试者中的安全性和药代动力学。全球目前尚无口服IL-17抑制剂获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400032390.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","688428","BK0239","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147407122","title":"诺诚健华宣布首例受试者接受潜在同类最佳口服IL-17Aa/Af抑制剂ICP-054一期临床试验给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1147407122","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147407122?lang=zh_cn&edition=full","pubTime":"2026-05-13 19:45","pubTimestamp":1778672709,"startTime":"0","endTime":"0","summary":"诺诚健华宣布,其潜在同类最佳口服IL-17Aa/Af抑制剂ICP-054的一期临床试验已完成首例受试者给药。ICP-054是一种新型口服小分子抑制剂,旨在高选择性地靶向IL-17A和IL-17F同源二聚体,从而可能为多种自身免疫性疾病提供新的治疗选择。该一期试验旨在评估ICP-054在健康受试者中的安全性、耐受性、药代动力学及药效学特征。公司表示,这一进展标志着其自身免疫性疾病管线开发的重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635660785","title":"诺诚健华(09969):ICP-054 (ZB021)的1期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2635660785","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635660785?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:48","pubTimestamp":1778669331,"startTime":"0","endTime":"0","summary":"智通财经APP讯,诺诚健华 发布公告,新型口服、潜在同类最佳的IL-17AA/AF抑制剂 ICP-054 的1期临床试验完成首例受试者入组。ICP-054的口服小分子特性,在用药便利性、患者依从性以及临床可及性上,有潜力比目前已获批的生物制剂IL-17疗法更具优势。待该研究完成后,本公司计划推进ICP-054 的临床开发,以确立其在自身免疫性疾病领域的概念验证。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK1574","688428","09969","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634698412","title":"每周股票复盘:诺诚健华(688428)将召开2025年度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2634698412","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634698412?lang=zh_cn&edition=full","pubTime":"2026-05-10 03:28","pubTimestamp":1778354891,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘,诺诚健华报收于26.35元,较上周的26.65元下跌1.13%。本周,诺诚健华5月8日盘中最高价报27.47元。本周关注点公司公告汇总:诺诚健华将于2026年5月14日召开2025年度暨2026年一季度业绩说明会。公司公告汇总诺诚健华医药有限公司将于2026年5月14日15:00-16:15通过上证路演中心和第一财经平台,以视频及线上文字互动形式召开2025年度暨2026年一季度集体业绩说明会。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000001385.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","BK1161","09969","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633342404","title":"诺诚健华(688428)披露证券变动月报表,5月8日股价下跌2.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633342404","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633342404?lang=zh_cn&edition=full","pubTime":"2026-05-08 18:08","pubTimestamp":1778234927,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘,诺诚健华报收于26.35元,较前一交易日下跌2.48%,最新总市值为464.98亿元。该股当日开盘27.2元,最高27.47元,最低26.25元,成交额达3.11亿元,换手率为4.35%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800032933.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","09969","BK0239","BK1574","161027","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124802514","title":"诺诚健华TYK2抑制剂ICP-488在华获批开展干燥综合征II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1124802514","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124802514?lang=zh_cn&edition=full","pubTime":"2026-05-08 08:31","pubTimestamp":1778200273,"startTime":"0","endTime":"0","summary":"诺诚健华宣布,其创新药物TYK2抑制剂ICP-488针对干燥综合征的II期临床试验申请已获得中国监管部门批准。该进展标志着公司在自身免疫疾病治疗领域取得重要突破。ICP-488作为高选择性TYK2抑制剂,通过精准调控JAK-STAT信号通路,有望为干燥综合征患者提供新的治疗选择。此次获批的II期临床试验将系统评估该药物在中国患者群体中的安全性和有效性,为后续临床开发奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633183907","title":"诺诚健华(688428)披露持股5%以上股东权益变动触及1%刻度公告,5月6日股价下跌1.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633183907","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633183907?lang=zh_cn&edition=full","pubTime":"2026-05-06 17:32","pubTimestamp":1778059940,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘,诺诚健华报收于26.31元,较前一交易日下跌1.28%,最新总市值为464.28亿元。该股当日开盘26.5元,最高26.68元,最低26.2元,成交额达2.79亿元,换手率为3.94%。公司近日披露《关于持股5%以上股东权益变动触及1%刻度的提示性公告》。本次权益变动方式为港股减持,不触及要约收购,不会导致公司控制权变化,对公司治理结构及持续经营无重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600027518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","688428","BK0239","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632623572","title":"每周股票复盘:诺诚健华(688428)股东权益变动触及1%刻度","url":"https://stock-news.laohu8.com/highlight/detail?id=2632623572","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632623572?lang=zh_cn&edition=full","pubTime":"2026-05-02 06:01","pubTimestamp":1777672902,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘,诺诚健华报收于26.65元,较上周的28.47元下跌6.39%。本周,诺诚健华4月27日盘中最高价报28.3元。本周关注点公司公告汇总:持股5%以上股东权益变动触及1%刻度,持股比例由8.21%减少至7.98%公司公告汇总诺诚健华医药有限公司持股5%以上股东Sunny View Holdings Limited及其一致行动人Wellesley Hill Holdings Limited、Grandview Irrevocable Trust、Renbin Zhao(赵仁滨)、施一公合计持有公司股份数量由14,481.7893万股减少至14,081.7893万股,持股比例由8.21%减少至7.98%,权益变动触及1%刻度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200003399.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","BK1574","688428","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630347483","title":"港股异动 | 诺诚健华(09969)涨近3% Mesutoclax治疗髓系恶性肿瘤研究入选ASCO 2026年会口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2630347483","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630347483?lang=zh_cn&edition=full","pubTime":"2026-04-28 09:51","pubTimestamp":1777341060,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,诺诚健华(09969)涨近3%,截至发稿,涨2.67%,报14.24港元,成交额2919.93万港元。消息面上,4月27日,据诺诚健华官微消息,公司宣布,自研新型BCL2抑制剂Mesutoclax(ICP-248)和新型BTK抑制剂奥布替尼的多项研究成果入选2026年美国临床肿瘤学会(ASCO)年会。其中,Mesutoclax治疗髓系恶性肿瘤的研究入选口头报告,Mesutoclax治疗B细胞恶性肿瘤的研究入选海报展示。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09969","BK0239","BK1574","688428","VXUS","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630236060","title":"诺诚健华(688428)披露2026年股东周年大会通知,4月27日股价下跌1.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630236060","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630236060?lang=zh_cn&edition=full","pubTime":"2026-04-27 18:36","pubTimestamp":1777286164,"startTime":"0","endTime":"0","summary":"截至2026年4月27日收盘,诺诚健华报收于27.91元,较前一交易日下跌1.97%,最新总市值为492.51亿元。该股当日开盘28.0元,最高28.3元,最低27.17元,成交额达3.52亿元,换手率为4.75%。近日,诺诚健华医药有限公司发布《关于召开2026年股东周年大会的通知》。公告显示,公司将于2026年6月16日召开2026年股东周年大会,会议采取现场与网络投票相结合方式,网络投票通过上海证券交易所系统进行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700034930.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","BK1161","688428","09969"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780151789207,"stockEarnings":[{"period":"1week","weight":-0.0298},{"period":"1month","weight":-0.0877},{"period":"3month","weight":0.0494},{"period":"6month","weight":-0.0607},{"period":"1year","weight":0.0635},{"period":"ytd","weight":0.1915}],"compareEarnings":[{"period":"1week","weight":-0.0108},{"period":"1month","weight":-0.0095},{"period":"3month","weight":-0.0227},{"period":"6month","weight":0.0463},{"period":"1year","weight":0.2096},{"period":"ytd","weight":0.0251}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"诺诚健华医药有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"20000人(较上一季度增加5.26%)","perCapita":"13417股","listingDate":"2022-09-21","address":"Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, Cayman Islands","registeredCapital":"0万元","survey":" 诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼。","listedPrice":11.03},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,688428,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}